In recent years, several radiotracers targeting the prostate-specific membrane antigen (PSMA) have been introduced. Some of them have had a high clinical impact on the treatment of patients with prostate cancer. However, the number of 18F-labeled tracers addressing PSMA is still limited. Therefore, we aimed to develop a radiofluorinated molecule resembling the structure of therapeutic PSMA-617. Methods: The nonradioactive reference compound PSMA-1007 and the precursor were produced by solid-phase chemistry. The radioligand 18F-PSMA-1007 was produced by a 2-step procedure with the prosthetic group 6-18F-fluoronicotinic acid 2,3,5,6-tetrafluorophenyl ester. The binding affinity of the ligand for PSMA and its internalization properties were evaluated in vitro with PSMA-positive LNCaP (lymph node carcinoma of the prostate) cells. Further, organ distribution studies were performed with mice bearing LNCaP and PC-3 (prostate cancer cell line; PSMA-negative) tumors. Finally, small-animal PET imaging of an LNCaP tumor-bearing mouse was performed. Results: The identified ligand had a binding affinity of 6.7 ± 1.7 nM for PSMA and an exceptionally high internalization ratio (67% ± 13%) in vitro. In organ distribution studies, high and specific tumor uptake (8.0 ± 2.4 percentage injected dose per gram) in LNCaP tumor-bearing mice was observed. In the small-animal PET experiments, LNCaP tumors were clearly visualized. Conclusion: The radiofluorinated PSMA ligand showed promising characteristics in its preclinical evaluation, and the feasibility of prostate cancer imaging was demonstrated by small-animal PET studies. Therefore, we recommend clinical transfer of the radioligand 18F-PSMA-1007 for use as a diagnostic PET tracer in prestaging and monitoring of prostate cancer.
In recent years, several radiotracers targeting the prostate-specific membrane antigen (PSMA) have been introduced. Some of them have had a high clinical impact on the treatment of patients with prostate cancer. However, the number of 18F-labeled tracers addressing PSMA is still limited. Therefore, we aimed to develop a radiofluorinated molecule resembling the structure of therapeutic PSMA-617. Methods: The nonradioactive reference compound PSMA-1007 and the precursor were produced by solid-phase chemistry. The radioligand 18F-PSMA-1007 was produced by a 2-step procedure with the prosthetic group 6-18F-fluoronicotinic acid 2,3,5,6-tetrafluorophenyl ester. The binding affinity of the ligand for PSMA and its internalization properties were evaluated in vitro with PSMA-positive LNCaP (lymph node carcinoma of the prostate) cells. Further, organ distribution studies were performed with mice bearing LNCaP and PC-3 (prostate cancer cell line; PSMA-negative) tumors. Finally, small-animal PET imaging of an LNCaP tumor-bearing mouse was performed. Results: The identified ligand had a binding affinity of 6.7 ± 1.7 nM for PSMA and an exceptionally high internalization ratio (67% ± 13%) in vitro. In organ distribution studies, high and specific tumor uptake (8.0 ± 2.4 percentage injected dose per gram) in LNCaP tumor-bearing mice was observed. In the small-animal PET experiments, LNCaP tumors were clearly visualized. Conclusion: The radiofluorinated PSMA ligand showed promising characteristics in its preclinical evaluation, and the feasibility of prostate cancer imaging was demonstrated by small-animal PET studies. Therefore, we recommend clinical transfer of the radioligand 18F-PSMA-1007 for use as a diagnostic PET tracer in prestaging and monitoring of prostate cancer.
Authors: C Gasch; C Düwel; K Kopka; C Kratochwil; M Vinsensia; M Eiber; T Maurer; U Haberkorn; B Hadaschik; F L Giesel Journal: Urologe A Date: 2017-01 Impact factor: 0.639
Authors: Kambiz Rahbar; Ali Afshar-Oromieh; Martin Bögemann; Stefan Wagner; Michael Schäfers; Lars Stegger; Matthias Weckesser Journal: Eur J Nucl Med Mol Imaging Date: 2018-03-14 Impact factor: 9.236
Authors: Martin T Freitag; Claudia Kesch; Jens Cardinale; Paul Flechsig; Ralf Floca; Matthias Eiber; David Bonekamp; Jan P Radtke; Clemens Kratochwil; Klaus Kopka; Markus Hohenfellner; Albrecht Stenzinger; Heinz-Peter Schlemmer; Uwe Haberkorn; Frederik Giesel Journal: Eur J Nucl Med Mol Imaging Date: 2017-10-16 Impact factor: 9.236
Authors: Evyn G Arnfield; Paul A Thomas; Matthew J Roberts; Anita M Pelecanos; Stuart C Ramsay; Charles Y Lin; Melissa J Latter; Peter L Garcia; David A Pattison Journal: Eur J Nucl Med Mol Imaging Date: 2021-06-16 Impact factor: 9.236
Authors: Sara Sheikhbahaei; Ali Afshar-Oromieh; Matthias Eiber; Lilja B Solnes; Mehrbod S Javadi; Ashley E Ross; Kenneth J Pienta; Mohamad E Allaf; Uwe Haberkorn; Martin G Pomper; Michael A Gorin; Steven P Rowe Journal: Eur J Nucl Med Mol Imaging Date: 2017-08-01 Impact factor: 9.236
Authors: Bastiaan M Privé; Peter H J Slootbeek; Babette I Laarhuis; Samhita Pamidimarri Naga; Maarten J van der Doelen; Ludwike W M van Kalmthout; Bart de Keizer; Samer Ezziddin; Clemens Kratochwil; Alfred Morgenstern; Frank Bruchertseifer; Marjolijn J L Ligtenberg; J Alfred Witjes; Inge M van Oort; Martin Gotthardt; Sandra Heskamp; Marcel J R Janssen; Winald R Gerritsen; James Nagarajah; Niven Mehra Journal: Prostate Cancer Prostatic Dis Date: 2021-07-12 Impact factor: 5.554
Authors: Lena M Mittlmeier; Matthias Brendel; Leonie Beyer; Nathalie L Albert; Andrei Todica; Mathias J Zacherl; Vera Wenter; Annika Herlemann; Alexander Kretschmer; Stephan T Ledderose; Nina-Sophie Schmidt-Hegemann; Wolfgang G Kunz; Jens Ricke; Peter Bartenstein; Harun Ilhan; Marcus Unterrainer Journal: Front Oncol Date: 2021-05-21 Impact factor: 6.244